Cytoplasmic β-catenin accumulation is a good prognostic marker in upper and lower gastrointestinal adenocarcinomas

Histopathology

Volumn 57, Issue 1, 2010, Pages 101-111

  Norwood, Michael G A ^a   Bailey, Neil ^b   Nanji, Manoj ^b,c   Gillies, Richard S ^b   Nicholson, Anna ^b,c   Ubhi, Sukh ^a   Darnton, Jane J ^d   Steyn, Richard S ^d   Womack, Chris ^e   Hughes, Andrew ^e   Hemingway, David ^a   Harrison, Rebecca ^a,b   Waters, Rachel ^f   Jankowski, Janusz A ^a,b,c  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d Birmingham Heartlands Hospital   (United States)

^e ASTRAZENECA   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

catenin; adenocarcinoma; cancer stage; Kaplan Meier; survival and P cadherin

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CTNNB1 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BIOACCUMULATION; CANCER STAGING; CELL MEMBRANE; CELLULAR DISTRIBUTION; COLORECTAL CARCINOMA; CORRELATION ANALYSIS; CYTOPLASM; ESOPHAGEAL ADENOCARCINOMA; GASTROINTESTINAL CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RETROSPECTIVE STUDY; SURVIVAL RATE; ADENOCARCINOMA; COLORECTAL TUMOR; ESOPHAGUS TUMOR; GASTROINTESTINAL TUMOR; KAPLAN MEIER METHOD; METABOLISM; MULTIVARIATE ANALYSIS; PATHOLOGY;

ADENOCARCINOMA; BETA CATENIN; COLORECTAL NEOPLASMS; CYTOPLASM; ESOPHAGEAL NEOPLASMS; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; KAPLAN-MEIER ESTIMATE;

EID: 77954559667     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03587.x     Document Type: Article

References (40)

1. Moayyedi P, Burch N, Akhtar-Danesh et al. Mortality rates in patients with Barrett's oesophagus. Aliment Pharmacol Ther 2008 27 316 320.
2. Quinn M, Babb P, Brock A, Kirby L, Jones J. Cancer trends in England and Wales 1950-1999. Studies on Medical and Population Subjects No. 66.
3. Newnham A, Quinn MJ, Babb P et al. Trends in the subsite and morphology of oesophageal and gastric cancer in England and Wales 1971-1998. Aliment. Pharmacol. Ther. 2003 17 665 676. (Pubitemid 36418890)
4. Lagergren J. Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut 2005 54 (Suppl. 1 i1 i5.
5. Hardy RG, Meltzer SJ, Jankowski JA. ABC of colorectal cancer. Molecular basis for risk factors. BMJ 2000 321 886 889 (Review).
6. Washington K, Chiappori A, Hamilton K et al. Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas. Mod. Pathol. 1998 11 805 813.
7. van Dekken H, Hop WC, Tilanus HW et al. Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett esophagus. Am. J. Clin. Pathol. 2008 130 745 753.
8. Wong NA, Pignatelli M. β-Catenin - a linchpin in colorectal carcinogenesis. Am. J. Pathol. 2002 160 389 401.
9. INK4A and is a region of low proliferation. Am. J. Pathol. 2001 159 1613 1617.
10. Bailey T, Biddleston L, Shepherd N, Barr H, Warner P, Jankowski J. Altered cadherin/catenin complexes in the dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation. Am. J. Pathol. 1998 152 135 144.
11. Bright-Thomas RM, Hargest R. APC, β-catenin and hTCF-4; an unholy trinity in the genesis of colorectal cancer. Eur. J. Surg. Oncol. 2003 29 107 117.
12. Dejmek J, Dejmek A, Safholm A, Sjolander A, Anderson T. Wnt-5a protein expression in primary Dukes B colon cancers identifies a subgroup of patients with good prognosis. Cancer Res. 2005 65 9142 9146.
13. Breuhahn K, Singh S, Schirmacher P et al. Large-scale N-terminal deletions but not point mutations stabilize beta-catenin in small bowel carcinomas suggesting divergent molecular pathways of small and large intestinal carcinogenesis. J. Pathol. 2008 215 300 307.
14. Falkenback D, Nilbert M, Oberg S, Johansson J. Prognostic value of cell adhesion in esophageal adenocarcinomas. Dis. Esophagus 2008 21 97 102.
15. Bryan R, Atherfold P, Yeo Y et al. Cadherin switching dictates the biology of transitional cell carcinoma in the bladder; in vivo and in vitro studies. J. Pathol. 2008 215 184 194.
16. Milicic A, Harrison L, Goodlad R et al. Ectopic expression of P-Cadherin by demethylation early in colon cancer leads to increased crypt fission. Cancer Res. 2008 68 7760 7768.
17. Hardy R, Tselepis C, Hoyland J et al. Aberrant P-cadherin expression is an early event in hyperplastic and dysplastic transformation of the colon. Gut 2002 50 513 519.
18. Gavert N, Ben-Ze'ev A. Beta-catenin signaling in biological control and cancer. J. Cell. Biochem. 2007 102 820 828.
19. Gebeshuber CA, Sladecek S, Grunert S. Beta-catenin/LEF-1 signalling in breast cancer - central players activated by a plethora of inputs. Cells Tissues Organs 2007 185 51 60.
20. Abbosh PH, Nephew KP. Multiple signaling pathways converge on beta-catenin in thyroid cancer. Thyroid 2005 15 551 561.
21. Verras M, Sun Z. Roles and regulation of Wnt signaling and beta-catenin in prostate cancer. Cancer Lett. 2006 237 22 32.
22. Salon C, Lantuejoul S, Eymin B, Gazzeri S, Brambilla C, Brambilla E. The E-cadherin-beta-catenin complex and its implication in lung cancer progression and prognosis. Future Oncol. 2005 1 649 660.
23. Powell SM, Zilz N, Beazer-Barclay Y et al. APC mutations occur early during colorectal tumorigenesis. Nature 1992 359 235 237.
24. Huber O, Korn R, McLaughlin J, Ohsugi M, Herrmann BG, Kemler R. Nuclear localization of beta-catenin by interaction with transcription factor LEF-1. Mech. Dev. 1996 59 3 10.
25. Hülsken J, Birchmeier W, Behrens J. E-cadherin and APC compete for the interaction with β-catenin and the cytoskeleton. J. Cell Biol. 1994 127 2061 2069.
26. Morin PJ, Sparks AB, Korinek V et al. Activation of beta-catenin-Tcf signalling in colon cancer by mutations in beta-catenin or APC. Science 1997 275 1787 1790.
27. Hao X, Tomlinson I, Ilyas M, Palazzo JP, Talbot IC. Reciprocity between membranous and nuclear expression of β-catenin in colorectal tumours. Virchows Arch. 1997 431 167 172.
28. Zhang B, Ougolkov A, Yamashita K, Takahashi Y, Mai M, Minamoto T. β-catenin and ras oncogenes detect most human colorectal cancer. Clin. Cancer Res. 2003 9 3073 3079.
29. Bellovin DI, Bates RC, Muzikansky A, Rimm DL, Mercurio AM. Altered localization of p120 catenin during epithelial to mesenchymal transition of colon carcinoma is prognostic for aggressive diseases. Cancer Res. 2005 65 10938 10945.
30. Mahmoud NN, Dannenberg AJ, Mestre J. Aspirin prevents tumors in a murine model of familial adenomatous polyposis. Surgery 1998 124 225 231.
31. Castellone MD, Teramoto H, Gutkind JS. Cyclooxygenase-2 and colorectal cancer chemoprevention: the β-catenin connection. Cancer Res. 2006 66 11085 11088.
32. Resnick MB, Routhier J, Konkin T, Sabo E, Pricolo VE. Epidermal growth factor receptor, c-MET, b-catenin and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin. Cancer Res. 2004 10 3069 3075.
33. Hugh TJ, Dillon SA, Taylor BA, Pignatelli M, Poston GJ, Kinsella AR. Cadherin-catenin expression in primary colorectal cancer: a survival analysis. Br. J. Cancer 1999 80 1046 1051.
34. Cheah PY, Choo PH, Yao J, Eu KW, Seow-Choen F. A survival-stratification model of human colorectal carcinomas with beta-catenin and p27kip1. Cancer 2002 95 2479 2486.
35. Gunther K, Brabletz T, Kraus C et al. Predictive value of nuclear beta-catenin expression for the occurrence of distant metastases in rectal cancer. Dis. Colon Rectum 1998 41 1256 1261.
36. Chung GG, Provost E, Kielhorn EP, Charette LA, Smith BL, Rimm DL. Tissue microarray analysis of ß-catenin in colorectal cancer shows nuclear phospho-ß-catenin is associated with a better prognosis. Clin. Cancer Res. 2001 7 4013 4020.
37. Zlobec I, Terracciano L, Jass JR et al. Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer. Virchows Arch. 2007 451 763 769.
38. Lugli A, Zlobec I, Minoo P et al. Prognostic significance of the wnt signalling pathway molecules APC, beta-catenin and E-cadherin in colorectal cancer: a tissue microarray-based analysis. Histopathology 2007 50 453 464.
39. Maruyama K, Ochiai A, Akimoto S et al. Cytoplasmic beta-catenin accumulation as a predictor of hematogenous metastasis in human colorectal cancer. Oncology 2000 59 302 309.
40. Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat. Rev. Cancer 2004 4 309 314.